Coverage / JNJ / Trade Card

JNJ

Johnson & Johnson

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 283.52 Healthcare - Drug Manufacturers - GeneralREDUCE ZONE
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 283.52
Buy <=wait / entry
USD 230.67
Trim >=take some off
USD 262.00
Thesis breakJohnson & Johnson guides 2027 operational sales growth below mid-single digits, ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case30%100 / 10030.0
Base case49%62 / 10030.4
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • 2026 operational sales guidance of $99.5-100.5B and adjusted EPS of $11.43-11.63, both exceeding Wall Street estimates despite hundreds of millions in drug pricing deal impact
  • Q2 2026 reported sales growth of 6.6% to $25.3B with raised full-year 2026 guidance to $101.1B sales and $11.68 adjusted EPS
  • Approvals of TREMFYA for psoriatic arthritis, CAPLYTA for schizophrenia relapse prevention, and Dual Energy THERMOCOOL SMARTTOUCH SF platform
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n